The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 26, 2019
Filed:
Jul. 30, 2015
Applicant:
Previvo Genetics, Inc., San Carlos, CA (US);
Inventors:
Sandra Ann Carson, Providence, RI (US);
John E. Buster, Providence, RI (US);
Moses Cesario, Piedmont, CA (US);
Steven Paul Woodard, Cupertino, CA (US);
Assignee:
Previvo Genetics, LLC, San Jose, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61B 17/435 (2006.01); A61B 17/425 (2006.01); A61B 50/13 (2016.01); A61B 50/31 (2016.01); A61K 9/00 (2006.01); A61K 31/215 (2006.01); A61K 31/57 (2006.01); A61K 31/573 (2006.01); A61K 31/575 (2006.01); A61K 31/58 (2006.01); A61K 38/08 (2019.01); A61K 38/09 (2006.01); A61K 38/24 (2006.01); A61K 45/06 (2006.01); C12Q 1/6883 (2018.01); A61B 17/42 (2006.01); A61B 50/18 (2016.01);
U.S. Cl.
CPC ...
A61B 17/435 (2013.01); A61B 17/42 (2013.01); A61B 17/425 (2013.01); A61B 50/13 (2016.02); A61B 50/31 (2016.02); A61K 9/0034 (2013.01); A61K 31/215 (2013.01); A61K 31/57 (2013.01); A61K 31/573 (2013.01); A61K 31/575 (2013.01); A61K 31/58 (2013.01); A61K 38/08 (2013.01); A61K 38/09 (2013.01); A61K 38/24 (2013.01); A61K 45/06 (2013.01); C12Q 1/6883 (2013.01); A61B 2017/4216 (2013.01); A61B 2050/185 (2016.02); A61B 2050/311 (2016.02); A61B 2217/005 (2013.01); A61B 2217/007 (2013.01); C12Q 2600/156 (2013.01);
Abstract
A kit having instructions for use for performing uterine lavage in a female patient includes a uterine lavage catheter configured for insertion into a woman's uterus to remove viable blastocysts from the uterus, and one or more first containers having a sufficient dosage amount of a GnRH antagonist to cause desynchronization of the endometrium of the patient prior to, during and/or following recovery of viable blastocysts from the uterus.